MicronJetTM – Hollow microneedles for intradermal injection

  • Demonstrated improved immunogenicity and/or dose sparing over subcutaneous and intramuscular delivery in clinical studies1-8,10
  • Demonstrated improved immunogenicity and/or potency over other intradermal devices in clinical studies3,5
  • Supported by extensive clinical experience
  • Consistent and shallow intradermal delivery4-9

The FDA cleared and CE marked MicronJetTM* is a microneedle-based device for intradermal drug delivery. The device is intended for intradermal injections of any substance or drug approved for delivery by this delivery route.
* Tradename May vary according to territory.

Keeping comfort in mind

Less than 1mm in size, the MicronJet™ microneedle offers an easy-to-use*, consistent4-9 and efficient intradermal alternative for practically painless8,9 delivery of drugs and vaccines. It can be used with any standard syringe to inject liquid substances directly into the skin, including vaccines, drugs, peptides and dermal fillers.
*user study; data on file

Research shows that by harnessing the robust immune system of the skin,
intradermal delivery with MicronJet600 can achieve better immunological results than intramuscular and subcutaneous delivery, with lower doses.

NEARLY PAINLESS

PRACTICALLY PAINLESS 1-8,9

LESS INTIMIDATING THAN REGULAR NEEDLE AND SYRINGE

LESS INTIMIDATING THAN REGULAR NEEDLE AND SYRINGE1,8

STUDIED IN INFANTS

TESTED IN WIDE AGE RANGE (PROVEN SAFETY AND IMMUNOGENICITY IN INFANTS AND ELDERLY) 7

Improved Immunogenicity and dose sparing over subcutaneous and intramuscular delivery1-8,10

The skin is one of the most potent immune organs of the body, naturally evolved for fighting pathogens However, injecting vaccines into the skin with a regular needle (using the Mantoux technique) is technically difficult.

The easy-to-use MicronJetTM has demonstrated:

  • Improved immunogenicity to full-dose vaccines (seasonal influenza, zoster)2,3,5,8
  • Significant dose sparing (4-40% of the dose) with various vaccines (seasonal and pandemic influenza, zoster, polio)1-8,10
  • Adjuvant sparing in seasonal influenza10

Improved immunogenicity/potency over other intradermal devices

NanoPass clinical trials have shown superior clinical outcomes over other intradermal devices in tests with different vaccinations

  • Improved immunogenicity over intradermal delivery using the Mantoux technique attributed to the shallowness and consistency of injection3
  • Better potency over Intanza®9, delivering the same results with one third of the dose5

Consistent and shallow intradermal delivery

The easy to use MicronJetTM provides one of most shallow and consistent forms of intradermal delivery. Its minute size (0.6mm) allows for shallow injection. Being barely visible to the naked eye makes it also significantly less painful than regular injections, as well as much less intimidating. It requires a short learning curve, enabling practitioners to quickly learn how to use the device, and adopt it as a leading alternative.

  • Blebs of >6 mm were observed 99% of the time, evaluated in over 1,000 injections on more than 800 subjects4-9
  • Significantly less painful and intimidating than a regular needle and syringe, with the potential for improved compliance1,8,9
  • Pediatrics applicability, as demonstrated by large Phase III study on 6-week-old infants7
  • Smallest hollow needle in the market allows for a practically painless injection1,8,9

3 Simple Application Steps illustrations

3 Simple Application Steps
3 Simple Application Steps
3 Simple Application Steps

* User study; data on file
** Marra F, Young F et al. meta analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenz Other Respir Viruses 2013; 7:584-603;
*** Micronjet600 Instructions For Use